Teligent, Inc. (TLGT) is a Major Pharmaceuticals company listed on NASDAQ. There were no new wire items for TLGT in the last 30 days. The most recent was published Oct 27, 2021.
Latest news
25 items- SECSEC Form 25-NSE filed by Teligent, Inc.25-NSE - Teligent, Inc. (0000352998) (Subject)
- SECTeligent, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Events That Accelerate or Increase a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Teligent, Inc. (0000352998) (Filer)
- PRTeligent to Pursue Asset Sale through Voluntary Chapter 11 ProcessBUENA, N.J., Oct. 14, 2021 /PRNewswire/ -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company ("Teligent" or the "Company"), today announced that the Company has, together with certain of its affiliates, filed for voluntary protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware to pursue a sale process that is intended to maximize the value of the Company. The Company began a marketing process ahead of the Chapter 11 filing to determine the level of market interest and is in ongoing discussions with several interested parties. The Company expects to consummate a sale of the entire busi
- INSIDERSEC Form 3 filed by new insider Benesch Joseph3 - Teligent, Inc. (0000352998) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lozynski Alyssa3 - Teligent, Inc. (0000352998) (Issuer)
- SECTeligent, Inc. filed SEC Form 8-K: Leadership Update8-K - Teligent, Inc. (0000352998) (Filer)
- SECTeligent, Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Teligent, Inc. (0000352998) (Filer)
- SECSEC Form 10-Q filed by Teligent, Inc.10-Q - Teligent, Inc. (0000352998) (Filer)
- PRTeligent, Inc. Announces Second Quarter 2021 Earnings Report and Provides Business Update–Update on FDA Inspection of Buena Facility–Assessing New Growth Opportunities in Injectables–Conference Call to Be Held on August 16, 2021 at 8:30 am Eastern Standard Time –Dial in: (877) 407-0792 US Toll Free Number (201) 689-8263 International Number Confirmation Number: 13721972 BUENA, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based generics pharmaceutical company, today announced its financial results for the second quarter of 2021 and provided a business update. "Product demand in our core business was impacted by a combination of factors, including remediation-related activities, the ongoing effects of the COVID-19 pandemic, and modest ge
- PRTeligent, Inc. to Hold Conference Call for Second Quarter 2021 Financial Results on Monday, August 16, 2021BUENA, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), ("Teligent" or the "Company"), a New Jersey based generics pharmaceutical company, today announced they will hold a conference call at 8:30AM ET on Monday, August 16th, 2021 to discuss the second quarter ended June 30, 2021 financial results and business update. Conference Call InformationDate: Monday, August 16, 2021Time: 8:30 a.m. Eastern TimeDial-in numbers: Toll Free: 877-407-0792 International: 201-689-8263Conference ID: 13721972 This call is available via webcast and can be accessed under News & Events in the Investor Relations section of Teligent, Inc.'s website at www.teligent.com. About Teligent, Inc.T
- SECTeligent, Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Teligent, Inc. (0000352998) (Filer)
- INSIDERSEC Form 4 filed by SABATINO THOMAS J JR4 - Teligent, Inc. (0000352998) (Issuer)
- INSIDERSEC Form 4 filed by Celentano John E4 - Teligent, Inc. (0000352998) (Issuer)
- INSIDERSEC Form 4 filed by BEN-MAIMON CAROLE4 - Teligent, Inc. (0000352998) (Issuer)
- INSIDERSEC Form 4 filed by Marth William S4 - Teligent, Inc. (0000352998) (Issuer)
- INSIDERSEC Form 4 filed by Pate R Carter4 - Teligent, Inc. (0000352998) (Issuer)
- INSIDERSEC Form 4: YACHMETZ PHILIP K converted options into 7,835 units of Common Stock and covered exercise/tax liability with 2,656 units of Common Stock to cover taxes (Amendment)4/A - Teligent, Inc. (0000352998) (Issuer)
- INSIDERSEC Form 4: YACHMETZ PHILIP K converted options into 7,835 units of Common Stock and covered exercise/tax liability with 2,656 units of Common Stock (tax withholding)4 - Teligent, Inc. (0000352998) (Issuer)
- SECSEC Form DEFA14A filed by Teligent, Inc.DEFA14A - Teligent, Inc. (0000352998) (Filer)
- PRTeligent, Inc. Announces Adjournment of Annual Meeting of StockholdersScheduled to Reconvene on July 21, 2021Company Urgently Encourages Stockholders to Vote BUENA, N.J., June 30, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company (the "Company"), announced today that its Annual Meeting of Stockholders, scheduled for June 18, 2021 and adjourned to June 30, 2021, was convened and adjourned without any business being conducted due to the fact that there were not sufficient votes to approve all of the proposals presented at the Annual Meeting. The Company is adjourning the meeting in order to solicit additional votes to meet the requirements for approval of the proposals presented. The Annual Mee
- SECSEC Form DEFA14A filed by Teligent, Inc.DEFA14A - Teligent, Inc. (0000352998) (Filer)
- PRTeligent, Inc. Announces Adjournment of Annual Meeting of StockholdersScheduled to Reconvene on June 30, 2021Company Urgently Encourages Stockholders to Vote BUENA, N.J., June 18, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company (the "Company"), announced today that its Annual Meeting of Stockholders, scheduled for June 18, 2021, was convened and adjourned without any business being conducted due to the fact that there were not sufficient votes to approve all of the proposals presented at the Annual Meeting. The Company is adjourning the meeting in order to solicit additional votes to meet the requirements for approval of the proposals presented. The Special Meeting will be reconvened at 10:
- INSIDERSEC Form 4 filed by Teligent, Inc.4 - Teligent, Inc. (0000352998) (Issuer)
- PRTeligent, Inc. Announces First Quarter 2021 Earnings Report and Provides Business Update–Continued Remediation Progress Being Made–Reiterating Prior Guidance of Informing FDA on Inspection Readiness During 3Q2021–Conference Call to Be Held on May 25, 2021 at 4:30 pm Eastern Standard Time –Dial in: (800) 708-4540 US Toll Free Number (847) 619-6397 US Number Confirmation Number: 50161966 BUENA, N.J., May 25, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based generics pharmaceutical company, today announced its financial results for the first quarter of 2021 and provided a business update. "As we prepare for the second half of 2021, we are pleased with the progress being made with respect to remediation, our strengthened capital position, and the recent
- PRTeligent, Inc. to Host Earnings CallNEW YORK, NY / ACCESSWIRE / May 25, 2021 / Teligent, Inc. (NASDAQ:TLGT) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 25, 2021 at 8:30 AM Eastern Time.To listen to the event live or access a replay of the call - visit https://www.investornetwork.com/event/presentation/79643To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company's profile.About Investor NetworkInvestor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on what's trending. Dedicated to both the professiona
TLGT FAQ
7 questionsWhat does Teligent, Inc. do?
Teligent, Inc., a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It is also involved in contract manufacturing and development business, including the development, manufacturing, filling, and package of topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and...What is the latest news on TLGT?
Quantisnow has not tracked any new filings, ratings or press releases for TLGT in the last 30 days. The most recent wire item was published on October 27, 2021.Where does TLGT stock trade?
Teligent, Inc. (TLGT) is listed on NASDAQ.What sector and industry is TLGT in?
Teligent, Inc. operates in the Health Care sector, Major Pharmaceuticals industry.When did Teligent, Inc. go public?
Teligent, Inc. (TLGT) completed its IPO in n/a.What companies are similar to TLGT?
Notable peers in the same industry include ADMS (Adamas Pharmaceuticals, Inc.), ADRO (Aduro Biotech, Inc.), ADXS (Advaxis, Inc.), ARPO (Aerpio Pharmaceuticals, Inc.), AIMT (Aimmune Therapeutics, Inc.). Compare TLGT side-by-side with any of them on Quantisnow.How can I track TLGT on Quantisnow?
Quantisnow aggregates Teligent, Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TLGT to receive live email and push alerts on every new disclosure.